Philip Morris International news

Outperformed tobacco industry (+21.4% vs +17%), strong pricing power, favorable product mix, smoke-free portfolio growth (42% of Q2 revenues), and double-digit EPS growth offset by structural cigarette volume declines and U.S. business pressure.

The company has successfully transformed its business model from declining traditional cigarettes to higher-margin smoke-free products (42% of revenue). Strong Q2 results with 10.4% revenue growth, 15.2% EPS growth, and five consecutive quarterly beats demonstrate the pivot is working. IQOS and ZYN show robust growth with expanding margins. However, sentiment is tempered by current valuation not being attractive, with only 6.6% annualized upside potential estimated by analysts.

Strong global growth (7% revenue growth achieved, 6.6% expected), successful smoke-free product expansion (IQOS, ZYN), geographic diversification across 170 markets, and higher absolute profitability ($11.4B net income). However, premium valuation (P/E 25.67x), exposure to geopolitical risks (Russia/Ukraine), and reliance on combustibles (58% of sales) limit upside potential.

Company is mentioned as sponsor of the Water Positivity Forum, indicating corporate commitment to sustainability initiatives, but no specific business impact or performance metrics are discussed.

The company faces a significant setback in its expansion strategy as India upholds its e-cigarette ban, blocking the launch of IQOS in a major market. India represents approximately 30% of PM's revenue and was identified as a key growth opportunity. This regulatory rejection limits the company's ability to diversify into smoke-free products in a strategically important market, despite strong global momentum in this segment.

Demonstrated premium-brand resilience with Marlboro reaching record 11% international cigarette share and strong international combustible pricing growth of 10%, indicating successful premium positioning and pricing power in international markets.

Philip Morris International is presented as a successful model for smokefree transformation with its Zyn nicotine pouches significantly outperforming Altria's On! brand. The company is also benefiting from a new contract manufacturing agreement with Altria, positioning it favorably in the industry's pivot away from traditional cigarettes.

ZYN is demonstrating strong market position with growing shipments and continued product innovation through new variants and increased U.S. investment, positioning the company favorably in the expanding nicotine pouch category.

PM is mentioned as a significant IYK holding at 11.40% and is recommended by The Motley Fool, but the article focuses on ETF comparison rather than individual stock sentiment.

Referenced as a descendant of Philip Morris that survived the 1998 Master Settlement Agreement tobacco lawsuits, used as a historical precedent example. No current investment recommendation implied.

Listed as a top holding (11.35%) in IYK but no specific analysis or recommendation provided.

As a major tobacco company, PMI is positioned to benefit from entering the growing nicotine pouch market, representing a diversification opportunity into tobacco alternatives.

Philip Morris is noted as a top holding in IYK (11.51%) but appears only as a factual portfolio detail without sentiment assessment.

Named as a dividend-paying blue-chip stock held in FDVV.

Mentioned as a competitor to Altria in the non-tobacco nicotine pouch market with its Zyn product. No specific investment recommendation or analysis provided in the article.

Mentioned as a comparative alternative and parent company of Swedish Match (supplier to Turning Point Brands), but not the primary focus of the analysis.

Recommended dividend stock with 3.2% forward yield, consistent annual dividend increases since 2008 spin-off, smoke-free products growing 14% organically and representing 43% of revenue, expected 12% EPS growth, and reasonable 22x forward earnings valuation.

Listed as a top IYK holding (11.02%); noted as a cigarette/vape stock that some investors may wish to avoid, but no inherent negative sentiment about the company.

Recommended as a defensive dividend stock with strong fundamentals despite declining smoking rates; smoke-free revenue grew 14% organically and represents 43% of revenue, with projected 7% and 10% CAGRs for revenue and EPS through 2028.

18 years of consecutive dividend growth, successful diversification into smoke-free products (41.5% of revenues), double-digit earnings growth, and favorable consumer trends supporting mid-single-digit dividend growth potential.

Strong revenue growth (9.1% YoY), robust EPS growth (16%), manageable payout ratio (81%), and consistent annual dividend increases. Growth in Zyn nicotine pouches and alternative products provides credible momentum, though regulatory risk exists.

Represented by Chief Sustainability Officer at a prominent sustainability summit, indicating active engagement in sustainability leadership and corporate environmental initiatives.

Included in XLP's top five holdings, demonstrating stability and consistent demand in uncertain markets.

Highlighted as a recession-resistant tobacco stock with strong recent performance. Praised for successful pivot to next-gen products (Zyn, Iqos), solid dividend yield of 3.7%, organic revenue growth of 6.5%, and reasonable 21.6x P/E valuation.

Strong position in nicotine market with successful expansion into smoke-free products (Zyn, Iqos). Smoke-free volumes grew 12.8% year-over-year with 19% organic gross profit growth, demonstrating pricing power and potential for significant dividend increases.